Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.25
Bid: 14.00
Ask: 14.50
Change: 0.00 (0.00%)
Spread: 0.50 (3.571%)
Open: 14.25
High: 14.25
Low: 14.00
Prev. Close: 14.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

2 Nov 2005 09:41

Angle PLC02 November 2005 NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIALRESPONSIBILITY OR CONNECTED PERSONS This form is intended for use by an issuer to make a RIS notification requiredby DR 3.1.4R(1). Please complete all relevant boxes should in block capital letters. 1. Name of the issuerAngle Plc 2. State whether the notification relates to (i) a transaction notified inaccordance with DR 3.1.4R(1)(a); or(ii) DR 3.1.4(R)(1)(b) a disclosure made in accordance with section 324 (asextended by section 328) of the Companies Act 1985; or(iii) both (i) and (ii)Both 3. Name of person discharging managerial responsibilities/directorIan Griffiths 4. State whether notification relates to a person connected with a persondischarging managerial responsibilities/director named in 3 and identify theconnected personN/a 5. Indicate whether the notification is in respect of a holding of the personreferred to in 3 or 4 above or in respect of a non-beneficial interestas in 3 above6. Description of shares (including class), debentures or derivatives orfinancial instruments relating to sharesOrdinary shares of 10p each 7. Name of registered shareholders(s) and, if more than one, the number ofshares held by each of themIan Griffiths 8 State the nature of the transactionPurchase of Ordinary Shares 9. Number of shares, debentures or financial instruments relating to sharesacquired8932 10. Percentage of issued class acquired (treasury shares of that class shouldnot be taken into account when calculating percentage)0.05% 11. Number of shares, debentures or financial instruments relating to sharesdisposedn/a 12. Percentage of issued class disposed (treasury shares of that class shouldnot be taken into account when calculating percentage)n/a 13. Price per share or value of transaction£1.115 per share 14. Date and place of transaction1 November 2005 15. Total holding following notification and total percentage holding followingnotification (any treasury shares should not be taken into account whencalculating percentage)529,546 shares. 3.17% 16. Date issuer informed of transaction1 November 2005 If a person discharging managerial responsibilities has been granted options bythe issuer complete the following boxes 17 Date of grant .................................... 18. Period during which or date on which it can be exercised .................................... 19. Total amount paid (if any) for grant of the option .................................... 20. Description of shares or debentures involved (class and number) ........................................................................ 21. Exercise price (if fixed at time of grant) or indication that price is to befixed at the time of exercise .................................... 22. Total number of shares or debentures over which options held followingnotification .................................... 23. Any additional information .................................... 24. Name of contact and telephone number for queriesIan Griffiths 01483 295830 Name and signature of duly authorised officer of issuer responsible for makingnotification .................................... Date of notification2 November 2005 END (1) An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.(2) An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8,13, 14, 16, 23 and 24.(3) An issuer making a notification in respect of options granted to a director /person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.(4) An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
22nd Jan 20207:00 amRNSSuccessful face-to-face meeting with FDA
8th Jan 202012:33 pmRNSNotice of Results
23rd Dec 20199:55 amRNSIssue of Equity
7th Nov 20197:00 amRNSCancer centre shows Parsortix use in melanoma
30th Oct 20192:44 pmRNSResult of AGM
30th Oct 20197:00 amRNSQ-submission to FDA containing headline data
8th Oct 20197:00 amRNSNotice of AGM
4th Oct 20195:54 pmRNSHolding(s) in Company
4th Oct 20197:00 amRNSEuropean patent granted for megakaryocyte analysis
13th Sep 20197:00 amRNSUse of Parsortix in head and neck cancer
10th Sep 20197:00 amRNSResearch with Parsortix in prostate cancer
4th Sep 20197:00 amRNSParsortix for Neuroendocrine Analysis in SCLC
29th Aug 20197:00 amRNSInitiation of Ovarian Cancer Study
31st Jul 20197:00 amRNSPrelim Results for the year ended 30 April 2019
22nd Jul 20197:00 amRNSUse of Parsortix for single cell analysis of CTCs
16th Jul 20199:19 amRNSHolding(s) in Company
12th Jul 201910:22 amRNSResult of General Meeting anf Total Voting Rights
28th Jun 20191:37 pmRNSNotice of Preliminary Results and Webcast
28th Jun 20191:08 pmRNSHolding(s) in Company
25th Jun 20195:19 pmRNSResult of Placing
25th Jun 20198:02 amRNSAccelerated bookbuild to raise £18.0m
21st Jun 20197:00 amRNSParsortix used to investigate immunotherapy target
5th Jun 20197:00 amRNSCompletion of Ovarian Cancer Pre-Study
31st May 20197:00 amRNSPositive Results from FDA Clinical Study
26th Apr 20197:00 amRNSIMMUNE SUPPRESSOR CELLS PROMOTE METASTASIS
18th Apr 20197:00 amRNSParsortix used in new cancer assessment technique
12th Apr 20197:00 amRNSLUNG CANCER STUDY USES ANGLE'S PARSORTIX SYSTEM
4th Apr 20197:00 amRNSAACR 2019
11th Mar 20197:00 amRNSHolding(s) in Company
7th Mar 20197:00 amRNSENROLMENT COMPLETE FOR FDA CLINICAL STUDY
28th Feb 20197:00 amRNSFIRST SUBJECTS ENROLLED IN OVARIAN CANCER STUDY
25th Feb 20197:00 amRNSCUSTOMER DEMONSTRATES NEW USE FOR PARSORTIX
11th Feb 20197:00 amRNSResearch into role of immune cells in cancer
31st Jan 20197:00 amRNSInterim Results
29th Jan 20197:00 amRNSNEW APPLICATION FOR PARSORTIX IN CANCER ANALYSIS
11th Jan 20192:05 pmRNSSecond Price Monitoring Extn
11th Jan 20192:00 pmRNSPrice Monitoring Extension
11th Jan 201911:05 amRNSSecond Price Monitoring Extn
11th Jan 201911:00 amRNSPrice Monitoring Extension
11th Jan 20199:05 amRNSSecond Price Monitoring Extn
11th Jan 20199:00 amRNSPrice Monitoring Extension
10th Jan 20194:41 pmRNSSecond Price Monitoring Extn
10th Jan 20194:36 pmRNSPrice Monitoring Extension
10th Jan 20194:01 pmRNSBREAKTHROUGH CANCER RESEARCH USING PARSORTIX
9th Jan 20197:00 amRNSNotice of Results
21st Dec 20187:00 amRNSIssue of LTIP Options and Share Options
28th Nov 20187:00 amRNSLEADING US HEMATOPATHOLOGIST APPOINTED AS ADVISOR
13th Nov 20185:10 pmRNSHolding(s) in Company
5th Nov 20187:00 amRNSAcquisition of outstanding shares
2nd Nov 20182:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.